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There is a wealth of data to show that mineralo-corticoid antagonists (MRA) reduce 
morbidity and mortality in patients with heart failure when left ventricular ejection fraction 
(LVEF) is reduced (HFrEF) and perhaps also when LVEF is fairly well-preserved 
(HFpEF)(1-5). Chin et al investigated whether the benefits of MRA were reduced amongst 
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patients prescribed aspirin(6). They concluded that no important interaction could be 
observed. If true, this is good news but still does not justify prescription of aspirin for patients 
with heart failure and coronary artery disease (CAD). The evidence that chronic aspirin 
therapy is safe or effective, regardless of LVEF, for any cardiovascular condition is not 
robust (7-10). Admittedly, there is good evidence that aspirin reduces coronary events and 
mortality when given for 4-12 weeks after an acute vascular event but any suggestion of a 
long-term effect owes more to the fertile imagination of cardiologists rather than to clinical 
trial data. In this era, which we pretend is one of evidence-based medicine, it is not to the 
credit of the medical community that aspirin enjoys such widespread abuse.   
Many patients with heart failure have CAD as a cause of cardiac dysfunction and heart failure 
and it may be an important co-morbidity in others. There is a widespread belief that these 
patients should receive an antiplatelet agent, usually aspirin, in order to reduce the risk of 
vascular events and prolong life. Unfortunately, there is no evidence to support such a view. 
Adequate randomized controlled trials comparing aspirin to placebo in patients with heart 
failure are lacking but the few data that exist are not reassuring(10, 11). There are concerns 
that aspirin might detract from the therapeutic benefits of agents that are known to improve 
outcome in heart failure, including ACE inhibitors and beta-blockers, possibly by blocking 
prostaglandin production resulting in impaired vasodilatation, renal dysfunction, sodium and 
water retention and hyponatraemia (7). Aspirin will also increase gastro-intestinal blood loss 
and may be at the root of the current epidemic of iron deficiency in the heart failure 
population(12). A key attribute of MRAs is that they increase sodium excretion, which may 
be attenuated by aspirin(13); a key problem with MRAs is a fall in glomerular filtration rate, 
which may be exacerbated by aspirin(14); each provides grounds for concern that aspirin may 
detract from the benefits of MRA. 
Page 3 of 8 
 
Several trials have compared aspirin either against clopidogrel or warfarin in patients with 
heart failure in sinus rhythm(11, 15, 16). Compared to aspirin, treatment with clopidogrel was 
associated with an improvement in renal function and a decline in natriuretic peptides but this 
has not, so far, translated into improved outcome(7, 17). For patients in sinus rhythm, 
warfarin reduces the risk of stroke but is not otherwise superior to aspirin(15, 16). An 
increased risk of heart failure hospitalizations with aspirin compared to warfarin noted in two 
studies(11, 15) was not substantiated in a third (16). Patients with heart failure and atrial 
fibrillation should, of course, receive an anti-coagulant. Newer anticoagulant agents appear 
associated with lower risks of stroke, intra-cranial haemorrhage and major bleeding compared 
to warfarin(18). For those in sinus rhythm, low-dose rivaroxaban (2.5mg twice daily) is being 
compared on top of background therapy(19); predominantly aspirin, unfortunately. However, 
there is also a head-to-head study of aspirin 100mg/day compared to rivaroxaban 5mg twice 
daily in patients with coronary or peripheral artery disease due to complete in 2018, although 
the study excludes patients with an LVEF <30%(20). 
Why, in the face of a lack of a positive trial do doctors continue to prescribe aspirin to 
patients with CAD? In the largest randomized controlled trial comparing aspirin and placebo 
after a myocardial infarction there were more deaths on aspirin (246 of 2267; 10.9%) than on 
placebo (219 of 2257; 9.7%)(21). Admittedly, patients were treated with aspirin at a dose of 
1,000mg/day but no large, long-term, placebo-controlled trial of aspirin after a myocardial 
infarction has ever used <300mg/day. Altogether, there were 10,859 patients in the six valid, 
randomized trials of long-term aspirin therapy after myocardial infarction. This showed a 
borderline significant 13% reduction in vascular deaths and 10% reduction in all-cause 
mortality (22). There is strong evidence of publication bias; the smaller the trial the larger the 
apparent effect(10). The subset of patients with heart failure in the two largest of these studies 
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had a higher mortality on aspirin than placebo(10). How much data is required to show how 
useless chronic aspirin therapy is? 
There has been only one clearly positive trial of aspirin for coronary disease(23). In the ISIS 
(International Study of Infarct Survival)-2 study, a course of aspirin lasting only 28 days 
reduced mortality at 35 days (the primary endpoint) compared to placebo, given double-blind. 
Importantly, the benefits of this 28 day course of aspirin persisted for at least 10 years, long 
after the course of aspirin was complete. Information on aspirin use after completion of the 
double-blind phase of ISIS-2 is lacking but as only 5% of patients in ISIS-1 were given 
aspirin and as there was no reason to change practice between these trials, the presumption 
must be that most patients did not receive aspirin after the randomized phase. More recent 
trials of aspirin and alternative anti-platelet agents initiated late after myocardial infarction 
have also failed to reduce mortality(24). Thus, it would appear that aspirin should be used 
after a myocardial infarction in much the same way as an antibiotic for pneumonia; a course 
of treatment is prescribed and then stopped.  
An oft quoted reason for prescribing antiplatelet agents is that they reduce platelet adhesion 
and occlusive thrombus formation and therefore the risk of myocardial infarction. However, 
the trigger for many coronary vascular events may be haemorrhage from fragile capillary in-
growth from the vasa vasorum(25). Thus, in stable disease, any benefit of anti-thrombotic 
agents from reduced thrombosis may be offset by an increase in plaque haemorrhage and 
rupture. Plaque is rich in red cell membrane derived lipids and haemosiderin suggesting that 
such events are common and might account for reports that aspirin accelerates plaque growth. 
So, are the conclusion of Chin et al valid? Probably not. The study was not powered to 
investigate the effects of eplerenone in subgroups. Of the 2,737 patients enrolled, more than 
30% of patients had atrial fibrillation and presumably most of these patients were not taking 
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aspirin because they were anti-coagulated. More patients taking aspirin developed 
hyperkalaemia on eplerenone (12.7% compared to 8.7%). The reduction in heart failure 
hospitalizations exerted by eplerenone was significantly lower amongst patients taking 
aspirin compared to those who were not (31% versus 52%; p=0.05) with similar trends, albeit 
not significant, for cardiovascular death (14% versus 31%) and all-cause mortality (18% 
versus 31%). These results could reflect the play of chance but with more data perhaps more 
of these trends would have become significant. An individual patient-data meta-analysis of 
randomized controlled trials of MRAs is warranted to address this issue. In the RALES 
(Randomized Aldactone Evaluation Study), AREA IN-CHF (Anti-remodelling Effect of 
Canrenone in Patients with Mild Chronic Heart Failure) and TOPCAT (Treatment of 
Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) studies, 37%, 
57% and 65% respectively were reported to be taking aspirin. However, observational data 
are no substitute for a randomized controlled trial of aspirin withdrawal in heart failure, 
which is sorely needed. 
In conclusion, this analysis does not justify the use of aspirin in patients with heart failure 
with or without coronary artery disease. Moreover, these data do not provide reassurance that 
aspirin does not detract from the benefits of eplerenone; rather the opposite. Whether or not 
there is an interaction between MRA and aspirin, there are concerns that aspirin has 
deleterious effects on haemodynamics, renal function, symptoms and outcome in patients 
with heart failure. There is no evidence that aspirin is of benefit for patients with heart failure. 
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